FourThought Financial’s Heron Therapeutics HRTX Stock Holding History

FourThought Financial’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$17K	Hold	4,023	–	–	﹤0.01%	901
2022 Q2	$11K	Hold	4,023	–	–	﹤0.01%	997
2022 Q1	$23K	Buy	4,023 +535	+15%	+$3.92K	﹤0.01%	864
2021 Q4	$32K	Hold	3,488	–	–	﹤0.01%	804
2021 Q3	$37K	Buy	3,488 +71	+2%	+$864	﹤0.01%	775
2021 Q2	$53K	Sell	3,417 -223	-6%	-$3.55K	0.01%	684
2021 Q1	$59K	Sell	3,640 -255	-7%	-$4.55K	0.01%	641
2020 Q4	$82K	Buy	+3,895	New	+$67.7K	0.01%	535

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

FourThought Financial's HRTX Position: Q3 2022 in Review

FourThought Financial held its Heron Therapeutics (HRTX) position steady in Q3 2022 at 4,023 shares worth $17K. The position accounts for ﹤0.01% of the portfolio, ranked #901.

FourThought Financial first reported a position in HRTX in Q4 2020 and has held it in 8 quarters since. The position peaked at $82K in Q4 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

FourThought Financial held 4,023 shares of Heron Therapeutics worth $17K as of Q3 2022.
FourThought Financial left its Heron Therapeutics share count unchanged in Q3 2022.
Heron Therapeutics made up ﹤0.01% of FourThought Financial's portfolio in Q3 2022, its #901 holding.
FourThought Financial first reported a position in Heron Therapeutics in Q4 2020 and has held it in 8 quarters since.
FourThought Financial's Heron Therapeutics position peaked at $82K in Q4 2020.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on FourThought Financial's 13F filing for Q3 2022, filed 21 Nov 2022.